ClinicalTrials.gg
CompletedNCT03545191Updated Mar 25, 2022Results posted

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

A Phase 3 interventional study of Daridorexant 25 mg and Daridorexant 50 mg in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 81 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
930
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
2nd of 16
930 · median 165
Started
2018
with 2 others
Phase 3
5 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
8 of 16
Idorsia Pharmaceuticals Ltd.

Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 3, and was the 5th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About daridorexant

daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The main purpose of this study is to assess efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

03

Conditions studied

  • Insomnia Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure;
  • Male or female aged ≥ 18 years;
  • Insomnia disorder according to criteria;
  • Insomnia Severity Index score ≥ 15;
  • Insufficient sleep quantity as collected subjectively in the sleep diary;
  • Women of must have a negative and urine pregnancy test and use the scheme up to at least 30 days after last study treatment intake.

Exclusion criteria

Exclusion Criteria:

  • below 18.5 or above 40.0 kg/m2;
  • Any lifetime history of of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, narcolepsy, or apnea/ hypopnea;
  • Cognitive behavioral therapy (CBT) only allowed if, the treatment started at least 1 month prior to Visit 3 and the subject agrees to continue this CBT throughout the study;
  • Self-reported usual daytime napping ≥ 1 hour per day and ≥ 3 days per week;
  • Acute or unstable psychiatric conditions diagnosed by the Mini International Neuropsychiatric Interview;
  • (MMSE) score \< 25 in subjects ≥ 50 years;
  • For female subjects: pregnant, lactating or planning to become pregnant during projected duration of the study;
  • History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
930 participants (actual)

Study arms

  • Experimental
    Daridorexant 25 mg

    Drug: Daridorexant 25 mg

  • Experimental
    Daridorexant 50 mg

    Drug: Daridorexant 50 mg

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Daridorexant will be administered as tablets, orally, once daily in the evening.

  • Daridorexant will be administered as tablets, orally, once daily in the evening.

  • OtherPlacebo

    Matching placebo will be administered as tablets, orally, once daily in the evening.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)

    "Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

    Time frame: From baseline to Month 1 (i.e. for up to 1 month)

  2. Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)

    "Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

    Time frame: From baseline to Month 3 (i.e. for up to 3 months)

  3. Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)

    "Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

    Time frame: From baseline to Month 1 (i.e. for up to 1 month)

  4. Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)

    "Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

    Time frame: From baseline to Month 3 (i.e. for up to 3 months)

Secondary outcomes

  1. Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)

    "Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

    Time frame: From baseline to Month 1 (i.e. for up to 1 month)

  2. Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)

    "Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

    Time frame: From baseline to Month 3 (i.e. for up to 3 months)

  3. Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score

    The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

    Time frame: From baseline to Month 1 (i.e. for up to 1 month)

  4. Change From Baseline to Month 3 in IDSIQ Sleepiness Domain Score

    The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

    Time frame: From baseline to Month 3 (i.e. for up to 3 months)

07

Results

Posted Mar 25, 2022

Participant flow

Participant flow — Overall Study
MilestoneDaridorexant 25 mgDaridorexant 50 mgPlacebo
Started310310310
Completed288285280
Not completed222530
Withdrew: Death100
Withdrew: Adverse event427
Withdrew: Other reasons3118
Withdrew: Withdrawal by subject131012
Withdrew: Lost to follow-up123

Outcome measures

PrimaryChange From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)

"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)
minutesDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)-18.40 (-22.126 to -14.674)-28.98 (-32.668 to -25.299)-6.20 (-9.928 to -2.475)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed effects model for repeated measures: change from baseline in WASO = baseline WASO + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -12.20 · 95% CI -17.435 to -6.961
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed effects model for repeated measures: change from baseline in WASO = baseline WASO + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -22.78 · 95% CI -27.996 to -17.567
PrimaryChange From Baseline to Month 3 in Wake After Sleep Onset (WASO)

"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

Time frame:
From baseline to Month 3 (i.e. for up to 3 months)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)
minutesDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)-22.97 (-26.955 to -18.988)-29.41 (-33.399 to -25.427)-11.11 (-15.131 to -7.088)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed effects model for repeated measures: change from baseline in WASO = baseline WASO + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -11.86 · 95% CI -17.494 to -6.23
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed effects model for repeated measures: change from baseline in WASO = baseline WASO + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -18.3 · 95% CI -23.945 to -12.661
PrimaryChange From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)

"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)
minutesDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)-28.17 (-31.509 to -24.827)-31.20 (-34.506 to -27.896)-19.85 (-23.177 to -16.515)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0005 (Mixed effects model for repeated measures: change from baseline in LPS = baseline LPS + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -8.32 · 95% CI -13.014 to -3.629
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed effects model for repeated measures: change from baseline in LPS = baseline LPS + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -11.35 · 95% CI -16.022 to -6.687
PrimaryChange From Baseline to Month 3 in Latency to Persistent Sleep (LPS)

"Latency to Persistent Sleep" is the time from start of recording to the beginning of the first continuous 20 epochs (i.e., 10 minutes) scored as non-awake, i.e., epochs scored as either sleep stage 1 (S1), sleep stage 2 (S2), sleep stage 3 (slow wave sleep) or REM, as determined by polysomnography.

Time frame:
From baseline to Month 3 (i.e. for up to 3 months)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)
minutesDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)-30.73 (-34.037 to -27.417)-34.80 (-38.118 to -31.490)-23.13 (-26.464 to -19.803)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0015 (Mixed effects model for repeated measures: change from baseline in LPS = baseline LPS + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -7.59 · 95% CI -12.265 to -2.923
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed effects model for repeated measures: change from baseline in LPS = baseline LPS + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -11.67 · 95% CI -16.348 to -6.994
SecondaryChange From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)

"Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)
minutesDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 1 in the Subjective Total Sleep Time (sTST)34.18 (28.718 to 39.645)43.62 (38.173 to 49.063)21.56 (16.101 to 27.022)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = = 0.0013 (Mixed effects model for repeated measures: change from baseline in sTST = baseline sTST + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: 12.62 · 95% CI 4.953 to 20.288
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = < 0.0001 (Mixed effects model for repeated measures: change from baseline in sTST = baseline sTST + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: 22.06 · 95% CI 14.405 to 29.708
SecondaryChange From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)

"Subjective Total Sleep Time" is the total sleep time reported by the participant in the sleep diary questionnaire. A positive change from baseline indicates an increase in the subjective Total Sleep Time. A negative change from baseline indicates a decrease in subjective Total Sleep Time.

Time frame:
From baseline to Month 3 (i.e. for up to 3 months)
Reported as:
Least squares mean · minutes
Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)
minutesDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 3 in the Subjective Total Sleep Time (sTST)47.83 (41.333 to 54.328)57.67 (51.171 to 64.168)37.90 (31.393 to 44.404)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = = 0.0334 (Mixed effects model for repeated measures: change from baseline in sTST = baseline sTST + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: 9.93 · 95% CI 0.782 to 19.082
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = < .00001 (Mixed effects model for repeated measures: change from baseline in sTST = baseline sTST + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: 19.77 · 95% CI 10.623 to 28.918
SecondaryChange From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score

The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score
Scores on a scaleDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 1 in Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) Sleepiness Domain Score-2.77 (-3.316 to -2.225)-3.77 (-4.309 to -3.224)-2.02 (-2.566 to -1.476)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = = 0.0547 (Mixed effects model for repeated measures: change from baseline in IDSIQ sleepiness domain score = baseline IDSIQ sleepiness domain score + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -0.75 · 95% CI -1.515 to 0.015
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = < .00001 (Mixed effects model for repeated measures: change from baseline in IDSIQ sleepiness domain score = baseline IDSIQ sleepiness domain score + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -1.75 · 95% CI -2.508 to -0.983
SecondaryChange From Baseline to Month 3 in IDSIQ Sleepiness Domain Score

The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) is a validated patient reported outcome instrument comprising 14 items (each using a numeric rating scale from 0 to 10) grouped into three domains (i.e., sleepiness, mood, and alert/cognition) reflecting daytime impairment of insomnia. The IDSIQ sleepiness domain has 4 items, and the domain score ranges from 0 to a maximum of 40, where a higher score indicates a greater burden. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Time frame:
From baseline to Month 3 (i.e. for up to 3 months)
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Month 3 in IDSIQ Sleepiness Domain Score
Scores on a scaleDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 3 in IDSIQ Sleepiness Domain Score-4.78 (-5.491 to -4.067)-5.70 (-6.405 to -4.987)-3.79 (-4.503 to -3.080)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0534 (Mixed effects model for repeated measures: change from baseline in IDSIQ sleepiness domain score = baseline IDSIQ sleepiness domain score + age group (\< 65; ≥ 65 years) + treatment + visit + treatment × visit + baseline × visit.) · Ls mean difference to placebo: -0.99 · 95% CI -1.990 to 0.014
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = = 0.0002 · Ls mean difference to placebo: -1.90 · 95% CI -2.905 to -0.905
Post-hocChange From Baseline to Month 1 in Log-transformed LPS (LSGM Ratio to Baseline)

Post-hoc analyses were performed using log-transformed LPS data, as the LPS values at baseline more closely resembled a log-normal distribution (skewed to the right) than a normal distribution.

Time frame:
From baseline to Month 1 (i.e. for up to 1 month)
Reported as:
Geometric least squares mean · minutes
Change From Baseline to Month 1 in Log-transformed LPS (LSGM Ratio to Baseline)
minutesDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 1 in Log-transformed LPS (LSGM Ratio to Baseline)0.49 (0.45 to 0.54)0.45 (0.41 to 0.49)0.62 (0.57 to 0.67)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0003 (Mixed effects model for repeated measures: log(value/baseline) = log(baseline) + age group(\< 65; ≥ 65 years) + treatment + visit + treatment x visit + log(baseline) x visit.) · Lsgm ratio to placebo: 0.79 · 95% CI 0.70 to 0.90
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed effects model for repeated measures: log(value/baseline) = log(baseline) + age group(\< 65; ≥ 65 years) + treatment + visit + treatment x visit + log(baseline) x visit.) · Lsgm ratio to placebo: 0.73 · 95% CI 0.65 to 0.82
Post-hocChange From Baseline to Month 3 in Log-transformed LPS (LSGM Ratio to Baseline)

Post-hoc analyses were performed using log-transformed LPS data, as the LPS values at baseline more closely resembled a log-normal distribution (skewed to the right) than a normal distribution.

Time frame:
From baseline to Month 3 (i.e. for up to 3 month)
Reported as:
Geometric least squares mean · minutes
Change From Baseline to Month 3 in Log-transformed LPS (LSGM Ratio to Baseline)
minutesDaridorexant 25 mgDaridorexant 50 mgPlacebo
Change From Baseline to Month 3 in Log-transformed LPS (LSGM Ratio to Baseline)0.43 (0.40 to 0.48)0.41 (0.37 to 0.45)0.56 (0.51 to 0.61)
Statistical analysis
  • Daridorexant 25 mg vs Placebo · Mixed Models Analysis · p = 0.0002 (Mixed effects model for repeated measures: log(value/baseline) = log(baseline) + age group(\< 65; ≥ 65 years) + treatment + visit + treatment x visit + log(baseline) x visit.) · Lsgm ratio to placebo: 0.78 · 95% CI 0.68 to 0.89
  • Daridorexant 50 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Mixed effects model for repeated measures: log(value/baseline) = log(baseline) + age group(\< 65; ≥ 65 years) + treatment + visit + treatment x visit + log(baseline) x visit.) · Lsgm ratio to placebo: 0.73 · 95% CI 0.64 to 0.83

Adverse events

Collected over Treatment-emergent AEs were AEs that started or worsened on or after the DB study treatment start date up to the earlier of 30 days after DB study treatment end date or the date of enrollment in the ID-078A303 extension study. The planned duration of DB treatment was 84 days ± 2 days, i.e., 12 weeks ± 2 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daridorexant 25 mg1/310 (0.3%)2/310 (0.6%)44/310 (14.2%)
Daridorexant 50 mg0/308 (0%)3/308 (1%)41/308 (13.3%)
Placebo0/309 (0%)7/309 (2.3%)35/309 (11.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDaridorexant 25 mgDaridorexant 50 mgPlacebo
SyncopeNervous system disorders0/3101/3082/309
DepressionPsychiatric disorders0/3100/3082/309
Post procedural haemorrhageInjury, poisoning and procedural complications0/3101/3080/309
Haemoglobin decreasedInvestigations0/3101/3080/309
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3101/3080/309
Renal colicRenal and urinary disorders0/3101/3080/309
Ankle fractureInjury, poisoning and procedural complications0/3100/3081/309
Panic attackPsychiatric disorders0/3100/3081/309
Anal abscessInfections and infestations0/3100/3081/309
Herpes zosterInfections and infestations0/3100/3081/309
Most frequent other events
Most frequent other events
EventDaridorexant 25 mgDaridorexant 50 mgPlacebo
NasopharyngitisInfections and infestations28/31024/30824/309
HeadacheNervous system disorders17/31020/30812/309

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Daridorexant 25 mgDaridorexant 50 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years189189188566
>=65 years121121122364
Age, Continuous
Age, Continuous(years)Daridorexant 25 mgDaridorexant 50 mgPlaceboTotal
Mean55.8 ± 15.355.5 ± 15.355.1 ± 15.455.4 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Daridorexant 25 mgDaridorexant 50 mgPlaceboTotal
Female215199210624
Male95111100306
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Daridorexant 25 mgDaridorexant 50 mgPlaceboTotal
Hispanic or Latino514451146
Not Hispanic or Latino259265259783
Unknown0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Daridorexant 25 mgDaridorexant 50 mgPlaceboTotal
Black or African American19302877
American Indian or Alaska Native0101
Native Hawaiian or other Pacific Islander1102
Asian3429
White287274278839
Other0022
08

Study locations

81 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Pulmonary Associates of the Southeast/WCR
    Birmingham, Alabama 35243, United States
  • Preferred Research Partners, Inc
    Little Rock, Arkansas 72211, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • St. Francis Sleep Allergy and Lung Institute
    Clearwater, Florida 33765, United States
  • Innovative Clinical Research, Inc.
    Hialeah, Florida 33012, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Canvas Clinical Research, LLC
    Lake Worth, Florida 33467, United States
  • BioMed Research Institute
    Miami, Florida 33126, United States
  • Clinical Site Partners, LLC
    Winter Park, Florida 32789, United States
  • LaPorte County Institute for Clinical Research
    Michigan City, Indiana 46360, United States
  • Kentucky Research Group
    Louisville, Kentucky 40218, United States
  • Helene Emsellem, MD
    Chevy Chase, Maryland 20815, United States
  • Infinity Medical Research, Inc.
    North Dartmouth, Massachusetts 02747, United States
  • Barrett Clinic
    La Vista, Nebraska 68128, United States
  • Clinical Research Center of Nevada
    Las Vegas, Nevada 89104, United States
  • Clinilabs NYC
    New York, New York 10019, United States
  • Research Carolina of Huntersville
    Huntersville, North Carolina 28078, United States
  • Coastal Carolina Healthcare
    New Bern, North Carolina 28562, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Oregon Center for Clinical Investigations,Inc
    Salem, Oregon 97301, United States
  • BTC of Lincoln
    Lincoln, Rhode Island 02865, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Bogan Sleep Consulting, LLC
    Columbia, South Carolina 29201, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Tri-State Mountain Neurology
    Johnson City, Tennessee 37604, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
  • Pulmonary Associates of Richmond
    Richmond, Virginia 23225, United States
  • Sleep Disorders Centers of the Mid-Atlantic
    Vienna, Virginia 22182, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Respiratory Clinical Trials
    Adelaide, 5065, Australia
  • Genesis Sleep Care Queensland
    Auchenflower, 4066, Australia
  • Melbourne Sleep Disorders Centre
    East Melbourne, 3002, Australia
  • The Woolcock Institute of Medical Research
    Glebe, 2037, Australia
  • Royal Melbourne Hospital, Department of Respiratory Medicine
    Parkville, 3052, Australia
  • Gold Coast University Hospital, Respiratory Medicine and Sleep Services
    Southport, 4215, Australia
  • Westmead Hospital, Department of Respiratory and Sleep Medicine
    Westmead, 2145, Australia
  • Tri-Hospital Sleep Laboratory West
    Mississauga, L5B 4M4, Canada
  • CRIUSMQ- CIUSSSCN, CETS (clinique du sommeil)
    Quebec, G1J 2G2, Canada
  • MedSleep
    Toronto, M4P 1P2, Canada
  • Jodha Tishon Inc.
    Toronto, M5G1N8, Canada
  • Scan Sleep Specialists
    København, 1053, Denmark
  • St Hedwig-Krankenhaus, Klinik für Schlaf- und Chronomedizin
    Berlin, 10115, Germany
  • emovis GmbH
    Berlin, 10629, Germany
  • Synexus Berlin Research Centre
    Berlin, 12627, Germany
  • Clinical Trial Center North GmbH & Co. KG
    Hamburg, 20251, Germany
  • Klinische Forschung Hamburg GmbH
    Hamburg, 20253, Germany
  • Klinische Forschung Karlsruhe GmbH
    Karlsruhe, 76137, Germany
  • Studienzentrum Wilhelmshöhe GmbH
    Kassel, 34131, Germany
  • Synexus Leipzig Research Centre
    Leipzig, 4103, Germany
  • Klinikum Rechts der lsar TU München Dept. of Psychiatry and Psychotherapy
    München, 81675, Germany
  • Kinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • ZMS Zentrum für medizinische Studien GmbH
    Warendorf, 48231, Germany
  • Ospedale San Raffaele - Centro per i Disturbi del Sonno San Raffaele - Ville-Turro - Pallazzina E
    Milano, 20127, Italy
  • IRCCS FONDAZIONE Istituto Neurologico Nazionale "Casimiro Mondino" - Centro di Ricerca Interdipartimentale per la SSclerosi Multipla (CRISM) -
    Pavia, 27100, Italy
  • Azienda Ospedaliero Universitaria Pisana - Ospedale S. Chiara - Centro di Medicina del Sonno - Clinica Neuroligica - Dipartimento de Neuroscienze
    Pisa, 56126, Italy
  • AOU Citta della Salute e della Scienza - Molinette - SSD Medicina del Sonno
    Torino, 10146, Italy
  • PI-House - Centrum Badań Klinicznych
    Gdańsk, 80-546, Poland
  • Ośrodek Medycyny Study Nurseu Instytutu Psychiatrii i Neurologii (Sleep Disorders Center)
    Warsaw, 02-957, Poland
  • EMC Instytut Medyczny SA, Przychodnia przy Łowieckiej
    Wroclaw, 50220, Poland
  • General Hospital Bel Medic, Center for Sleep disorders
    Belgrade, 11000, Serbia
  • Medigroup - Health Center Dr Ristic (MediGroup Dom zdravlja "Dr Ristic") - Neurology Department
    Novi Beograd, 11070, Serbia
  • Centro Médico Teknon - Medicina del Sueño
    Barcelona, 8017, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 8025, Spain
  • Hospital Universitari Vall d'Hebron - Neurophisiology Deparment - Sleep Unit
    Barcelona, 8035, Spain
  • Hospital General de Castellon
    Castelló de la Plana, 12004, Spain
  • Instituto de Investigaciones del Sueno
    Madrid, 28036, Spain
  • San Carlos University Hospital - Servicio de Neurofisiología Clínica
    Madrid, 28040, Spain
  • Hospital Universitario Araba - Unidad Funcional de Trastornos del Sueño
    Vitoria-Gasteiz, 1004, Spain
  • Hospital MAZ - Neurophisiology and Sleep Department
    Zaragoza, 50015, Spain
  • KSM Bad Zurzach, Klinik für Schlafmedizin
    Bad Zurzach, 5330, Switzerland
  • Universitäre Psychiatrische Kliniken Basel (Upk)
    Basel, 4002, Switzerland
  • Universitätsklinik für Neurologie, Inselspital Bern, Schlaf-Wach-Epilepsie-Zentrum
    Bern, 3010, Switzerland
  • Zentrum für Schlafmedizin Zürcher Oberland, Zürcher RehaZentrum Wald
    Wald, 8636, Switzerland
  • Zentrum für Schlafmedizin GZO AG Spital Wetzikon
    Wetzikon, 8620, Switzerland
09

References and documents

Publications

  • Hudgens S, Phillips-Beyer A, Newton L, Seboek Kinter D, Benes H. Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Patient. 2021 Mar;14(2):249-268. doi: 10.1007/s40271-020-00474-z. Epub 2020 Nov 1. PubMed 33131027 ↗
  • Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Kinter DS, Roth T; investigators. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022 Feb;21(2):125-139. doi: 10.1016/S1474-4422(21)00436-1. Erratum In: Lancet Neurol. 2022 Mar;21(3):e3. doi: 10.1016/S1474-4422(22)00029-1. Lancet Neurol. 2022 Jun;21(6):e6. doi: 10.1016/S1474-4422(22)00144-2. PubMed 35065036 ↗
  • Fietze I, Bassetti CLA, Mayleben DW, Pain S, Seboek Kinter D, McCall WV. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial. Drugs Aging. 2022 Oct;39(10):795-810. doi: 10.1007/s40266-022-00977-4. Epub 2022 Sep 13. PubMed 36098936 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jan 2020, 19 months.

Results were first posted in Mar 2022, 2 years 2 months after primary completion. A results delay was requested in Oct 2020.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 19 months is close to that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2018
First posted
Jun 4, 2018
StartActual
Jun 4, 2018
Primary completionActual
Jan 25, 2020
CompletionActual
Feb 25, 2020
Results delay requested
Oct 20, 2020
Results first posted
Mar 25, 2022
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03545191
Responsible party
Sponsor
First posted
Jun 4, 2018
Start date
Jun 4, 2018
Primary completion
Jan 25, 2020
Completion
Feb 25, 2020
Results posted
Mar 25, 2022
Last update
Mar 25, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion